App 4C - Quarterly Cash Flow Report - March 2020 Qtr
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- FDA Awards Orphan Drug Designation for Pancreatic Cancer
- Dr. John Lambert appointed as Managing Director
- Appendix 4C Cash Flow - Dec 2019 Qtr
- Amplia Therapeutics Undertakes Placement
- App 4D - Financial Report Half Year Ended 30 Sep 2019
Later from Amplia Therapeutics
- Quarterly Activities Report - March 2020 Qtr
- FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
- Preliminary Final Report - YE 31 March 2020
- Preliminary Toxicology Studies Support Phase1 Clinical Trial
- Entitlement Offer to Fund Phase 1 Clinical Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics